Our findings of lower NPTX2 concentrations in sporadic FTD compared with PPD and controls are in line with our previous pilot study and with a recent study among patients with genetic forms of FTD, in which symptomatic mutation carriers showed lower concentrations of CSF NPTX2 compared with controls [13]. The gene discussed is NPTX2; the disease is frontotemporal dementia.